Present study | Registration study | |
---|---|---|
Number of patients (N) | 217 | 253 |
Gender, n (%) | ||
Male | 183 (84) | NR |
Female | 34 (16) | NR |
Age, years | ||
Median (IQR) | 69 (62–76) | NR |
< 65, n (%) | 73 (34) | 135 (53) |
≥ 65, n (%) | 144 (66) | 118 (47) |
ECOG PS, n (%) | ||
0 | 101 (47) | 72 (28) |
1 | 100 (46) | 181 (72) |
≥ 2 | 16 (7) | 0 (0) |
Creatinine clearance, n (%) | ||
> 60 | 125 (58) | 134 (54) |
40–60 | 75 (35) | 104 (42) |
< 40 | 17 (8) | 10 (4) |
Number of metastatic sites, n (%) | ||
1 site | 127 (58) | 62 (25) |
≥ 2 sites | 90 (42) | 191 (75) |
Visceral involvement, n (%) | 115 (53) | 187 (74) |
Metastatic sites, n (%) | ||
Lymph nodes only | 103 (47) | NR |
Liver | 47 (22) | NR |
Lungs | 70 (32) | NR |
Bone | 79 (36) | NR |
Brain | 2 (1) | NR |
Other tissue (not visceral) | 32(15) | NR |
Prior pelvic irradiation, n (%) | 16 (7) | 57 (23) |
Prior therapy with platinum-based regimen, n (%) | ||
Cisplatin | 122 (56) | 164 (65) |
Carboplatin | 91 (42) | 75 (30) |
Other platinum combination | 4 (2) | 14 (5) |